Monday December 18th 2017

FDA Approves New Dose of Copaxone To Be Taken Less Frequently

On January 28, the FDA approved a new dose of glatiramer acetate (Copaxone,® Teva Pharmaceuticals Industries, Ltd.) injected under the skin three times per week, at double the standard 20mg/mL dose, for relapsing MS. This long-approved MS disease-modifying therapy is normally taken every day. The approval was based on benefits and safety demonstrated by a company-sponsored, one-year, phase III trial comparing the higher, less-frequent dose of Copaxone with placebo.

See the original article here:  

FDA Approves New Dose of Copaxone To Be Taken Less Frequently

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]